GLPG Quote, Financials, Valuation and Earnings

Celyad Oncology SA has a net margin of -286.67% compared to Galapagos NV's net margin of --. Galapagos NV's return on equity of -16.48% beat Celyad Oncology SA's return on equity of --.

Galapagos NV has a consensus price target of $27.45, signalling downside risk potential of -13.07%. On the other hand Celyad Oncology SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Galapagos NV has higher upside potential than Celyad Oncology SA, analysts believe Galapagos NV is more attractive than Celyad Oncology SA.

Galapagos NV has a beta of 0.185, which suggesting that the stock is 81.495% less volatile than S&P 500. In comparison Celyad Oncology SA has a beta of 0.162, suggesting its less volatile than the S&P 500 by 83.796%.

Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celyad Oncology SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galapagos NV pays -- of its earnings as a dividend. Celyad Oncology SA pays out -- of its earnings as a dividend.

Galapagos NV quarterly revenues are $83.2M, which are larger than Celyad Oncology SA quarterly revenues of --. Galapagos NV's net income of -$238.4M is higher than Celyad Oncology SA's net income of --. Notably, Galapagos NV's price-to-earnings ratio is 21.30x while Celyad Oncology SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 6.57x versus 37.01x for Celyad Oncology SA. Usually stocks with elevated PS ratios are considered overvalued.

MDxHealth SA has a net margin of -286.67% compared to Galapagos NV's net margin of -29.2%. Galapagos NV's return on equity of -16.48% beat MDxHealth SA's return on equity of -548.42%.

Galapagos NV has a consensus price target of $27.45, signalling downside risk potential of -13.07%. On the other hand MDxHealth SA has an analysts' consensus of $7.0400 which suggests that it could grow by 95.56%. Given that MDxHealth SA has higher upside potential than Galapagos NV, analysts believe MDxHealth SA is more attractive than Galapagos NV.

Galapagos NV has a beta of 0.185, which suggesting that the stock is 81.495% less volatile than S&P 500. In comparison MDxHealth SA has a beta of -557,066.812, suggesting its less volatile than the S&P 500 by 55706781.163%.

Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MDxHealth SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galapagos NV pays -- of its earnings as a dividend. MDxHealth SA pays out -- of its earnings as a dividend.

Galapagos NV quarterly revenues are $83.2M, which are larger than MDxHealth SA quarterly revenues of $27.4M. Galapagos NV's net income of -$238.4M is lower than MDxHealth SA's net income of -$8M. Notably, Galapagos NV's price-to-earnings ratio is 21.30x while MDxHealth SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 6.57x versus 1.72x for MDxHealth SA. Usually stocks with elevated PS ratios are considered overvalued.

Nyxoah SA has a net margin of -286.67% compared to Galapagos NV's net margin of -1195.73%. Galapagos NV's return on equity of -16.48% beat Nyxoah SA's return on equity of -96.48%.

Galapagos NV has a consensus price target of $27.45, signalling downside risk potential of -13.07%. On the other hand Nyxoah SA has an analysts' consensus of $11.23 which suggests that it could grow by 129.58%. Given that Nyxoah SA has higher upside potential than Galapagos NV, analysts believe Nyxoah SA is more attractive than Galapagos NV.

Galapagos NV has a beta of 0.185, which suggesting that the stock is 81.495% less volatile than S&P 500. In comparison Nyxoah SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nyxoah SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galapagos NV pays -- of its earnings as a dividend. Nyxoah SA pays out -- of its earnings as a dividend.

Galapagos NV quarterly revenues are $83.2M, which are larger than Nyxoah SA quarterly revenues of $2.3M. Galapagos NV's net income of -$238.4M is lower than Nyxoah SA's net income of -$27.6M. Notably, Galapagos NV's price-to-earnings ratio is 21.30x while Nyxoah SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 6.57x versus 29.02x for Nyxoah SA. Usually stocks with elevated PS ratios are considered overvalued.

UCB SA has a net margin of -286.67% compared to Galapagos NV's net margin of --. Galapagos NV's return on equity of -16.48% beat UCB SA's return on equity of 13.88%.

Galapagos NV has a consensus price target of $27.45, signalling downside risk potential of -13.07%. On the other hand UCB SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Galapagos NV has higher upside potential than UCB SA, analysts believe Galapagos NV is more attractive than UCB SA.

Galapagos NV has a beta of 0.185, which suggesting that the stock is 81.495% less volatile than S&P 500. In comparison UCB SA has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.475%.

Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UCB SA offers a yield of 0.55% to investors and pays a quarterly dividend of $0.79 per share. Galapagos NV pays -- of its earnings as a dividend. UCB SA pays out 15.96% of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Galapagos NV quarterly revenues are $83.2M, which are larger than UCB SA quarterly revenues of --. Galapagos NV's net income of -$238.4M is higher than UCB SA's net income of --. Notably, Galapagos NV's price-to-earnings ratio is 21.30x while UCB SA's PE ratio is 38.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 6.57x versus 7.52x for UCB SA. Usually stocks with elevated PS ratios are considered overvalued.